IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...

SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...

Please provide your email address to receive an email when new articles are posted on . Patients with severe degenerative mitral regurgitation saw sustained benefits with a novel transcatheter edge-to ...

Edwards Lifesciences Corp. ((EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is currently conducting a pivotal clinical trial titled ‘Edwards PASCAL Transcatheter ...

BOSTON, MA—(UPDATED) Patients with severe symptomatic degenerative mitral regurgitation (MR) ineligible for surgery fare just as well when treated with the Pascal device (Edwards Lifesciences) as ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — A novel mitral valve transcatheter edge-to-edge repair system was noninferior to an existing system in ...

BOSTON -- The Pascal device for edge-to-edge mitral valve repair was as safe and effective as the MitraClip device, the pivotal CLASP IID trial showed. In a pre-specified interim analysis of the first ...

SAN FRANCISCO, CA—For patients with symptomatic degenerative mitral regurgitation (DMR) and a prohibitive surgical risk, transcatheter edge-to-edge repair (TEER) with either of two approved devices ...

The US Food and Drug Administration (FDA) has approved the PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) in patients with degenerative mitral ...